Introduction {#section5-2398212818794820}
============

Hyperglycaemia occurs in over 60% of stroke patients with no previous history of diabetes and in 90% of diabetics ([@bibr28-2398212818794820]). Post-stroke hyperglycaemia (PSH) is associated with increased mortality, poor functional outcomes and larger final infarct sizes ([@bibr4-2398212818794820]; [@bibr27-2398212818794820]; [@bibr39-2398212818794820]). The association between hyperglycaemia and unfavourable prognosis is particularly evident in ischaemic stroke patients without a known history of diabetes mellitus ([@bibr6-2398212818794820]; [@bibr38-2398212818794820]). Glucose-lowering treatment for PSH carries a risk of hypoglycaemia ([@bibr15-2398212818794820]; [@bibr23-2398212818794820]; [@bibr40-2398212818794820]), raising safety concerns over this type of intervention. Therefore, elucidation of the pathophysiological mechanisms that lead to the detrimental effects of PSH may present alternative therapeutic avenues. We previously reported that hyperglycaemia in rats, *at levels typically experienced by stroke patients*, exerted detrimental effects on ischaemic brain tissue in the very acute period following induction of focal cerebral ischaemia ([@bibr43-2398212818794820]). Using diffusion-weighted magnetic resonance imaging (MRI) to define the temporal evolution of tissue damage, as defined by the apparent diffusion coefficient (ADC), larger ADC-defined lesions were observed in hyperglycaemic compared to normoglycaemic rats as early as 1 h after middle cerebral artery occlusion (MCAO). These data indicate that hyperglycaemia adversely affects the ischaemic brain in the very acute period after arterial occlusion.

Given the very early nature of the detrimental influence of PSH, one of the potential mechanisms is an effect on cerebral perfusion. If hyperglycaemia reduces cerebral blood flow (CBF), this could increase the severity of the ischaemic insult leading to a larger perfusion deficit and potentially more brain tissue damage. There is some evidence from preclinical studies that hyperglycaemia can reduce CBF in both non-ischaemic rat brain ([@bibr11-2398212818794820], [@bibr12-2398212818794820]), and after induction of focal cerebral ischaemia in rats ([@bibr20-2398212818794820]), and cats ([@bibr45-2398212818794820]). Several mechanisms for hyperglycaemia-induced reductions in CBF have been proposed from these preclinical studies including turbulent cerebral capillary blood flow resulting in damage to the endothelium ([@bibr17-2398212818794820]), altered osmolality and increased cerebral vascular resistance ([@bibr10-2398212818794820]), impairment of nitric oxide-dependent dilatation of cerebral arterioles via the activation of protein kinase C ([@bibr26-2398212818794820]) and a co-operative effect of hyperglycaemia and cortical spreading depression on CBF ([@bibr46-2398212818794820]). However, limitations of previous animal studies include the use of either type I diabetes models or induction of blood glucose levels that are much higher than what is observed in acute stroke patients ([@bibr24-2398212818794820]). We therefore sought to determine whether clinically relevant hyperglycaemia increases the severity of cerebral ischaemia and causes greater ischaemic damage in the acute period following induction of focal cerebral ischaemia in rats. We used two distinct techniques for assessing CBF in separate experiments: ^99m^Tc-D, L-hexamethylpropyleneamine oxime (^99m^Tc-HMPAO) blood flow autoradiography which provides high spatial and anatomical resolution at a single time point and pseudo-continuous arterial spin labelling (pCASL) for repeated measurements of CBF in the same animal over time. Diffusion weighted imaging (DWI) was performed alongside pCASL to measure ADC lesion volume in order to calculate the volume of perfusion--diffusion (PI-DWI) mismatch tissue during the first 4 h after MCAO. PI-DWI mismatch tissue is widely used to identify the ischaemic penumbra and MRI studies in acute ischaemic stroke patients show that larger infarcts in patients with admission hyperglycaemia are associated with reduced penumbral salvage ([@bibr29-2398212818794820]; [@bibr35-2398212818794820]). The suggestion that PI-DWI mismatch tissue might be highly susceptible to hyperglycaemia through the accelerated conversion of hypoperfused at-risk tissue to infarction provided a rationale for comparing the volume of PI-DWI mismatch tissue in glucose- and vehicle-injected animals. The issue of when hyperglycaemia occurs in stroke patients is very hard to define since in most cases hyperglycaemia is present on hospital arrival 3--6 h after symptom onset, but in most of these cases it predates the stroke as it reflects underlying disordered glycaemic control. A smaller group then develops hyperglycaemia at some stage of their initial 48 h hospital stay, but it is the first group with 'admission hyperglycaemia' that is of clinical interest as this is the group for whom the outcome after stroke is poor ([@bibr28-2398212818794820]). The current study was not designed to mimic the time course of hyperglycaemia in stroke patients which is heterogeneous, but rather to test the mechanistic hypothesis that clinically relevant levels of hyperglycaemia *at the time of MCAO* would increase the perfusion deficit.

Materials and methods {#section6-2398212818794820}
=====================

Animals {#section7-2398212818794820}
-------

Experiments were carried out under licence from the UK Home Office and were subject to the Animals (Scientific Procedures) Act, 1986. All experiments were performed in compliance with the ARRIVE (Animal Research; Reporting In Vivo Experiments) guidelines. Adult, male Wistar rats (Harlan, UK) weighing between 280 and 370 g were used in all experiments and prior to surgery were housed in standard cages in groups of 2--4. In recovery experiments, rats were singly housed after recovery until termination. All rats were randomised to receive a vehicle or glucose injection using an online randomisation plan generator ([www.randomization.com](http://www.randomization.com)). The vehicle and glucose solutions for injection were prepared by technical staff and therefore, the investigators who performed surgery, autoradiography, MRI scanning and analyses were blinded to the treatment group identity throughout. Investigators (L.T., K.M.) who performed the autoradiographic and MRI analyses were unblinded to rat identity only after data analyses had been scrutinised and finalised by other authors.The investigators who performed surgery also recorded blood glucose levels and were therefore not blinded to the glucose level results during the procedure. Rats were fasted overnight (in pairs) prior to surgery with free access to water.

MCAO surgery and glucose administration {#section8-2398212818794820}
---------------------------------------

Surgeries were performed first thing in the morning. Animals were intubated and artificially ventilated under isoflurane anaesthesia (5% induction, 2.5% maintenance in 70% N~2~O/30% O~2~). The right femoral artery was cannulated for continuous recording of mean arterial blood pressure (MABP) and monitoring of blood pH, PaCO~2~, PaO~2~ and blood glucose. The femoral vein was cannulated in some animals for intravenous administration of ^99m^Tc-HMPAO. Permanent focal cerebral ischaemia was achieved by occluding the distal portion of the middle cerebral artery (MCA) using diathermy, a modification of the method described by Tamura and colleagues ([@bibr42-2398212818794820]). The left MCA was exposed via a craniectomy and the point at which the MCA crosses the inferior cerebral vein was identified and a \~1 mm length of the artery above and below this point was electrocoagulated with diathermy forceps. The MCA was then cut with microscissors to confirm complete occlusion.

Ten minutes prior to MCAO animals received a single intraperitoneal injection (10 mL/kg) of either a 15% glucose solution in distilled water or vehicle solution. We have previously demonstrated that with this protocol, blood glucose rises to hyperglycaemic levels within 1 h ([@bibr43-2398212818794820]). Arterial blood glucose levels were measured 20 min before MCAO to obtain a baseline reading and at selected time points after MCAO using a glucometer (Accu-Chek, Roche, Germany).

CBF measurement using ^99m^Tc-HMPAO autoradiography {#section9-2398212818794820}
---------------------------------------------------

At 1 h post-MCAO 225MBq of ^99m^Tc-HMPAO in 0.6 mL saline was injected intravenously over 30 s. Five minutes following injection, rats were euthanised by decapitation and brains were removed, frozen in isopentane (−45°C) and 20 µm sections cut on a cryostat. Sections spanning the entire cerebrum were mounted onto glass slides and autoradiograms were prepared from these sections by exposing them, alongside pre-calibrated ^14^C standards (21 − 174 × 10^3^ nCi/g ^99m^Tc tissue equivalents), for 1 h. The ^99m^Tc tissue concentrations on the autoradiograms were analysed using an image analysis system (MCID; Imaging Research, Linton, Cambridge, UK) and were considered to be proportional to CBF. CBF was assessed using two different analyses: threshold and region of interest (ROI).

Threshold analysis {#section10-2398212818794820}
------------------

CBF in the cortex ipsilateral to the occluded MCA was normalised to the contralateral cortex to minimise the influence of inter-animal variability. To assess the severity of the CBF deficit 1 h post-MCAO, a threshold approach to the analysis of the autoradiograms was taken. CBF in the ischaemic cortex was examined using three thresholds: 0%--43%, 43%--75% and 75%--100% of the non-ischaemic cortex. The 0%--43% range was selected to represent severely hypoperfused or ischaemic core tissue. This has previously been shown to be a viability threshold identifying irreversibly damaged tissue after MCAO in rats using MRI ([@bibr37-2398212818794820]). The 43%--75% and 75%--100% thresholds were selected to represent moderately and mildly hypoperfused tissue, respectively. For each animal, autoradiographic images of 10 coronal levels (ranging 4.7 mm anterior to Bregma and 8 mm posterior to Bregma) were captured for threshold analysis. The area of the ipsilateral cortex at each threshold was measured and expressed as a percentage of the area of the ipsilateral cortex. For each coronal level, CBF was measured on three consecutive sections and the average was calculated. Representative autoradiograms depicting threshold analysis at coronal level 3 (0.3 mm posterior to Bregma) are shown in [Figure 1](#fig1-2398212818794820){ref-type="fig"}.

![Representative autoradiograms depicting threshold analysis of ^99m^Tc-HMPAO uptake. The cortex ipsilateral to MCAO (outlined in green) and contralateral cortex (outlined in red) was manually delineated (top left). The pale region in the ipsilateral cortex represents an area with reduced uptake of ^99m^Tc-HMPAO indicating reduced CBF induced by MCAO in the cerebral cortex. In subsequent images, the green pixels represent the area of the ipsilateral cortex where ^99m^Tc-HMPAO uptake was within 0%--43%, 43%--75% and 75%--100% of the contralateral cortex.](10.1177_2398212818794820-fig1){#fig1-2398212818794820}

ROI analysis {#section11-2398212818794820}
------------

A total of 22 distinct brain structures were selected for ROI analysis and a rat brain atlas ([@bibr30-2398212818794820]) was used to identify each structure in the autoradiograms. Autoradiographic images depicting the uptake of ^99m^Tc-HMPAO within selected brain sections were captured for ROI analysis. The rectangle drawing tool on the image analysis system was used to place a box over each structure in the ipsilateral hemisphere and the optical density measured. ^99m^Tc-HMPAO tissue concentration (nCi/g) was then calculated with reference to the optical densities of the standards. The same tool was used to place an identical sized box over the equivalent ROI in the contralateral hemisphere to calculate the concentration there. The ^99m^Tc-HMPAO tissue concentration from the ROI in the ipsilateral hemisphere was then expressed as a percentage of that in the contralateral hemisphere. For each ROI examined, the ^99m^Tc-HMPAO concentration was determined in three autoradiographic sections and the average was taken.

CBF measurement using MRI perfusion imaging {#section12-2398212818794820}
-------------------------------------------

MRI data were acquired using a Bruker Biospec 7T/30 cm system with a gradient coil (internal diameter = 121 mm, 400 mT/m) and a 72 mm birdcage resonator. Following surgery to induce MCAO rats was immediately transferred to a Perspex rat cradle and the head was restrained using tooth and ear bars. A linear phased array surface receiver coil (2 cm diameter) was placed above the head of the animal. Body temperature was monitored using a rectal thermocouple and maintained within physiological range (37°C ± 0.5°C) using a temperature-controlled water jacket. MABP was monitored via the femoral artery catheter attached to a blood pressure transducer, which was in turn connected to a computer in combination with an MP150 Biopac System (Biopac Systems Inc, USA) and Acknowledge software (Linton). MRI scanning was performed each hour post-MCAO for a total of 4 h. During each hour, quantitative imaging of CBF was carried out on six coronal slices within the MCA territory using a form of pCASL. The sequence employs a Spin-Echo Echo Planar Imaging (SE-EPI) module (echo time = 20 ms, repetition time = 7000 ms, matrix = 96 × 96, field of view (FOV) = 25 × 25 mm^2^, slice thickness 1.5 mm, 16 averages, 4 shots) preceded by 50 hyperbolic secant inversion pulses in a 3 s train ([@bibr3-2398212818794820]). A T~1~-weighted image was also acquired each hour using an EPI inversion recovery sequence (echo time = 20 ms, repetition time = 10,000 ms, matrix = 96 × 96, FOV = 25 × 25 mm, slice thickness 1.5 mm, 16 averages, 4 shots, using 16 inversion times from 200 to 7700 ms).

Quantitative CBF maps (units: mL/100 g/min) were calculated using the formula for continuous labelling ([@bibr47-2398212818794820]), which has been described elsewhere ([@bibr3-2398212818794820]; [@bibr34-2398212818794820]). ImageJ software was used to process raw data sets.) Labelled pCASL images were generated when blood was excited by a radiofrequency pulse (RF) at the level of the carotid arteries in the neck to produce an endogenous 'label'. These were subtracted from control images (no RF pulse) and then divided by control images to generate relative CBF maps. Quantitative CBF maps were generated by dividing the relative CBF map by the T~1~ values generated from the T~1~ map. Perfusion deficit maps were produced by applying a previously published abnormal perfusion threshold of 30 mL/100 g/min ([@bibr37-2398212818794820]) to all pCASL images (see explanation below).

DWI {#section13-2398212818794820}
---

Following MCAO, DWI reveals evidence of ischaemic injury to brain tissue within minutes of the arterial occlusion and can be used serially over the acute stroke period (0--4 h) to track changes in lesion size. DWI was therefore also performed each hour in order to map the evolution of the ischaemic lesion (SP-EPI, echotime = 22.5 ms; repetition time = 4 s, in-plane resolution of 260 µm; three directions: x, y, z; B values: 0, 1000 s/mm^2^, eight slices 1.5 mm thickness). Quantitative ADC maps (mm^2^/s) were calculated from the DWI scans using ParaVision v5 (Bruker, Germany) and subsequently analysed using ImageJ software. On all ADC maps, the ADC lesion volume was calculated using a previously published threshold of 0.53 × 10^−3^ mm^2^/s ([@bibr37-2398212818794820]).

There is currently no consensus on where to set the perfusion and diffusion thresholds to accurately define perfusion and diffusion lesions in rodent models of focal cerebral ischaemia ([@bibr5-2398212818794820]). To generate ADC and CBF thresholds, [@bibr37-2398212818794820] adjusted the ADC and CBF values on respective ADC and CBF maps until the ADC- and CBF-defined lesion volumes were numerically equal to infarct volumes measured at 24 h post-MCAO. The absolute ADC and CBF thresholds established in the study by [@bibr37-2398212818794820] were 0.53 × 10^−3^ mm^2^/s and 30 mL/100 g/min, respectively, and thus, they were applied in the current study.

T~2~-weighted imaging {#section14-2398212818794820}
---------------------

The time course of T~2~ signal change reflects net tissue water content and this changes slowly over the early hours of ischaemia ([@bibr16-2398212818794820]). However, by 24 h, T~2~ imaging delineates the extent of the ischaemic lesion and is the most regularly used MRI sequence to determine the extent of the infarct. Animals were recovered from anaesthesia after pCASL and DWI MRI scanning for 24 h at which time they were re-anaesthetised (5% isoflurane in 70/30 N~2~O/O~2~ mixture) and transferred to the MRI scanner where anaesthesia was maintained via a facemask (2.5% isoflurane 70/30 N~2~O/O~2~ mixture). A RARE (rapid acquisition with refocused echoes) T~2~-weighted sequence (effective TE: 46.8 ms, TR: 5000 s; in-plane resolution of 97 µm; 16 slices of 0.75 mm thickness) was used to determine infarct volume at 24 h post-MCAO. The infarct was defined as the hyperintense area on T~2~-weighted images. ImageJ was used to measure the area of the hyperintense region on each of the 16 slices and infarct volume was calculated by summing the total area across the 16 slices and multiplying by the slice thickness. The volumes of the ipsilateral and contralateral hemispheres were also determined. All infarct volume calculations were corrected for oedema using published equations ([@bibr13-2398212818794820]; [@bibr41-2398212818794820]).

Calculation of the penumbra from the perfusion--diffusion mismatch {#section15-2398212818794820}
------------------------------------------------------------------

A spatial assessment of the perfusion--diffusion mismatch was carried out on each of the six coronal slices of the CBF maps. The mismatch was defined using previously published ADC (0.53 × 10^−3^ mm^2^/s) and CBF (30 mL/100 g/min) thresholds ([@bibr37-2398212818794820]). The area of mismatch on each of the six slices was measured, summed and multiplied by the slice thickness (1.5 mm) to obtain the volume of mismatch tissue. This was repeated for each time point after MCAO.

Western blot analysis {#section16-2398212818794820}
---------------------

Brains were available from all animals that completed the MRI scanning and therefore as an observational analysis (not part of the formal study), these were analysed by Western blotting to examine proteins that are associated with ischaemic brain damage (membrane-associated spectrin and microtubule-associated protein 2). Following the T~2~ scan at 24 h after MCAO, the ipsilateral ischaemic cortex was dissected and homogenised in lysis buffer (250 mM sucrose, 10 mM Hepes, 1 mM sodium orthovanadate, 1 mM sodium pyrophosphate, 1 mM ethylenediaminetetraacetic acid (EDTA) 0.2 mM phenylmethylsulfonyl fluoride) supplemented with a protease inhibitor cocktail (Sigma, UK). Lysates were then separated into a crude membrane fraction by centrifugation. The protein concentrations of the samples from the membrane fraction were determined using a bicinchoninic acid (BCA) protein assay kit (Fisher Scientific, UK). 10 g of protein from the membrane fraction of each animal was electrophoresed on 4%--20% Criterion™ TGX pre-cast gels (Bio-Rad, UK) and transferred to a nitrocellulose membrane. The membrane was blocked with 5% milk powder in 1× Tris-buffered saline containing 1% Tween-20 (in Tris-buffered saline) to minimise non-specific binding for 1 h then incubated overnight at 4°C with the following primary antibodies: monoclonal mouse anti-spectrin (MAB1622, Millipore, UK), polyclonal rabbit anti-MAP2 (ab32454, Abcam, UK), both diluted at 1:200,000, and monoclonal mouse anti-beta-Actin (ab8224, Abcam, UK) (diluted at 1:400,000). The membrane was incubated with the secondary antibody (1:10,000, Dako) and Bio-Rad's Clarity Western enhanced chemi-luminescence (ECL) substrate was used according to the manufacturer's protocol. Membranes were visualised using the Bio-Rad Chemidoc MP system and ImageJ software was used to estimate the amount of protein in each sample.

Sample size calculation {#section17-2398212818794820}
-----------------------

A sample size calculation was performed based on an 80% power (1 − β = 0.8) and a 95% significance level (α = 0.05). The effect size (50 mm^3^) and standard deviation (36.5) were determined from a previous in-house study ([@bibr43-2398212818794820]) and were based on the change in ADC-derived lesion volume at 1 h post-MCAO exhibited in hyperglycaemic compared to normoglycaemic WKY rats. The number of animals per group was calculated to be 9.

Inclusion/exclusion criteria {#section18-2398212818794820}
----------------------------

A total of 26 animals were entered into the autoradiography study and 5 were excluded (2 glucose-treated rats and 3 vehicle-treated rats). Three of the five rats died due to significant blood loss during the diathermy step of MCAO. One of the rats died during the injection of ^99m^Tc-HMPAO and one rat was excluded from analysis due to the presence of a haemorrhage in the brain which was detected as it was being sectioned. The final group sizes for the autoradiography study were n = 10 for the vehicle treatment group and n = 11 for the glucose treatment group. A total of 27 animals were entered into the MRI study and 4 were excluded (3 vehicle-treated rats and 1 glucose-treated rat) as they died during or after the MRI scanning protocol. Three further rats (all glucose treated) were excluded from the study due to the presence of subdural haematomas on T~2~-weighted images. The final group sizes for the MRI study analysis were n = 10 for the vehicle treatment group and n = 10 for the glucose treatment group.

Statistical analysis {#section19-2398212818794820}
--------------------

Physiological variables, CBF ROI measurements, T~2~-derived infarct volumes and relative protein levels were analysed using an unpaired Student's t-test. Line graphs of the threshold analysis data were analysed using a two-way analysis of variance (ANOVA). ADC lesion volumes, perfusion deficit volumes and perfusion--diffusion mismatch were assessed using a repeated measures two-way analysis of variance (RM two-way ANOVA) with Bonferroni's post-test. A Pearson's correlation was used to measure the linear correlation between T~2~-derived infarct volume at 24 h post-MCAO and blood glucose levels at 4 h post-MCAO. Differences between groups were considered to be statistically significant when P \< 0.05. Data are expressed as mean ± standard deviation or presented as scatterplots with the mean indicated. Where images are presented from the median animal of each group, these are the median animals from the T~2~-derived infarct volume results.

Results {#section20-2398212818794820}
=======

Physiological variables {#section21-2398212818794820}
-----------------------

Physiological variables in animals from both autoradiography and MRI studies were within normal limits and there were no significant differences in body weight, MABP, body temperature, blood gases and pH between the vehicle and glucose groups ([Tables 1](#table1-2398212818794820){ref-type="table"} and [2](#table2-2398212818794820){ref-type="table"}). In both autoradiography and MRI studies, blood glucose levels were measured 20 min prior to MCAO to obtain a baseline reading. Mean blood glucose levels at baseline ranged from 4.9 to 7.3 mmol/L and were comparable between groups in each study ([Tables 1](#table1-2398212818794820){ref-type="table"} and [2](#table2-2398212818794820){ref-type="table"}). Following glucose or vehicle administration, blood glucose levels increased significantly in animals that received glucose compared to those that received the vehicle, in which blood glucose levels remained close to baseline levels. Blood glucose levels ranged from 10.8 to 11.9 mmol/L in animals that received glucose and from 5.6 to 6.8 mmol/L in animals that received vehicle ([Tables 1](#table1-2398212818794820){ref-type="table"} and [2](#table2-2398212818794820){ref-type="table"}).

###### 

Physiological variables for the ^99m^Tc-HMPAO blood flow study.

![](10.1177_2398212818794820-table1)

  Physiological parameter                Vehicle (n = 10)   Glucose (n = 11)
  -------------------------------------- ------------------ ----------------------------------------------------------------------
  Body weight (g)                        313 ± 2            322 ± 3
  MABP (mmHg)                            85 ± 4             90 ± 4
  PaCO~2~ (mmHg)                         39 ± 6             40 ± 4
  PaO~2~ (mmHg)                          125 ± 1            120 ± 2
  pH                                     7.4 ± 0.1          7.4 ± 0.1
  Temperature (°C)                       37 ± 0.2           37 ± 0.2
  Blood glucose (mmol/L) at baseline     7.3 ± 1.3          7.1 ± 1.6
  Blood glucose (mmol/L) 1 h post-MCAO   6.8 ± 0.8          11.9 ± 2.6[\*\*\*](#table-fn2-2398212818794820){ref-type="table-fn"}

Body weight was measured on the day of MCAO. MABP, body temperature, pH, PaO~2~ and PaCO~2~ were measured approximately every 30 min during surgery and the data are expressed as the mean ± standard deviation over the entire surgical period. Blood glucose was measured 20 min before MCAO and 1 h post-MCAO. All statistical comparisons by Student's unpaired t-test.

P \< 0.0001 compared with vehicle.

###### 

Physiological variables for MRI the study.

![](10.1177_2398212818794820-table2)

  Physiological parameter   Time post-MCAOBaseline   1h                                                                       2h                                                                       3h                                                                       4h
  ------------------------- ------------------------ ------------------------------------------------------------------------ ------------------------------------------------------------------------ ------------------------------------------------------------------------ ------------------------------------------------------------------------
  Vehicle (n = 10)                                                                                                                                                                                                                                                              
   Body weight (g)          321 ± 25                                                                                                                                                                                                                                            
   MABP (mmHg)              92 ± 9                   91 ± 10                                                                  90 ± 10                                                                  90 ± 8                                                                   89 ± 6
   PaCO~2~ (mmHg)           35 ± 10                  36 ± 10                                                                  41 ± 11                                                                  41 ± 11                                                                  39 ± 5
   PaO~2~ (mmHg)            126 ± 2                  125 ± 2                                                                  121 ± 2                                                                  131 ± 3                                                                  123 ± 3
   pH                       7.41 ± 0.1               7.38 ± 0.04                                                              7.39 ± 0.04                                                              7.40 ± 0.03                                                              7.35 ± 0.04
   Temperature (°C)         37 ± 0.3                 37.4 ± 0.4                                                               37.3 ± 0.5                                                               37.3 ± 0.3                                                               37.1 ± 0.1
   Blood glucose (mmol/L)   4.9 ± 0.9                5.6 ± 1.5                                                                6.5 ± 1.2                                                                6.2 ± 0.8                                                                6.1 ± 1.1
  Glucose (n = 10)                                                                                                                                                                                                                                                              
   Body weight (g)          336 ± 17                                                                                                                                                                                                                                            
   MABP (mmHg)              97 ± 10                  88 ± 5                                                                   87 ± 11                                                                  85 ± 11                                                                  89 ± 7
   PaCO~2~ (mmHg)           37 ± 11                  38 ± 6                                                                   37 ± 9                                                                   36.5 ± 5                                                                 41 ± 9
   PaO~2~ (mmHg)            132 ± 2                  123 ± 2                                                                  122 ± 1                                                                  131 ± 2                                                                  132 ± 3
   pH                       7.47 ± 0.04              7.37 ± 0.1                                                               7.35 ± 0.07                                                              7.37 ± 0.1                                                               7.37 ± 0.04
   Temperature (°C)         37.0 ± 0.2               37.2 ± 0.4                                                               37.1 ± 0.6                                                               37.4 ± 0.4                                                               37.2 ± 0.6
   Blood glucose (mmol/L)   5.9 ± 1.1                11.3 ± 2.9[\*\*\*\*](#table-fn3-2398212818794820){ref-type="table-fn"}   11.2 ± 2.3[\*\*\*\*](#table-fn3-2398212818794820){ref-type="table-fn"}   11.1 ± 1.4[\*\*\*\*](#table-fn3-2398212818794820){ref-type="table-fn"}   10.8 ± 1.5[\*\*\*\*](#table-fn3-2398212818794820){ref-type="table-fn"}

Body weight was measured on the day of MCAO. MABP, PaCO~2~, PaO~2~, pH, temperature and blood glucose were measured at baseline (20 min before MCAO) and at each hour for 4 h after MCAO. The data are expressed as mean ± standard deviation. Statistical comparisons by Student's unpaired t-test or repeated measures two-way ANOVA with Bonferroni's post-test (blood glucose). ^\*\*\*\*^P \< 0.0001 compared with vehicle.

^99m^Tc-HMPAO autoradiography {#section22-2398212818794820}
-----------------------------

We assessed CBF using autoradiography and MRI in two separate experiments. The results from the ^99m^Tc-HMPAO experiments are presented in [Figure 2](#fig2-2398212818794820){ref-type="fig"}. In all autoradiograms, regions of ischaemia were visible in the ipsilateral cortex where there was reduced uptake of the radiotracer ^99m^Tc-HMPAO ([Figure 2(a)](#fig2-2398212818794820){ref-type="fig"}). Autoradiograms were analysed using both a threshold and ROI-based analysis. For the threshold analysis, different thresholds were applied to the ipsilateral cortex of 10 coronal levels in order to grade the severity of ischaemia into three categories: severely (0%--43%), moderately (43%--75%) and mildly (75%--100%) reduced relative to the contralateral cortex. The area of the ipsilateral cortex at each threshold, at each coronal level, was measured and expressed as a percentage of the area of the ipsilateral cortex ([Figure 2(b)](#fig2-2398212818794820){ref-type="fig"}). The differences between groups were not statistically significant at any of the thresholds examined. Using ROI analysis, we found that there were notable decreases in ^99m^Tc-HMPAO uptake in ipsilateral, compared to contralateral brain structures supplied by the distal branches of the MCA in both the vehicle and glucose groups ([Table 3](#table3-2398212818794820){ref-type="table"}). There were no statistically significant differences between the vehicle and glucose groups in any of the 22 structures examined ([Table 3](#table3-2398212818794820){ref-type="table"}).

![Autoradiograms showing ^99m^Tc-HMPAO concentration in coronal levels 3, 4 and 5, at 1 h post-MCAO from a representative vehicle and glucose-treated rat (a). Ischaemia is visible topographically within the ipsilateral cortex in both groups to a similar extent. Line graphs illustrating the % area of the ipsilateral cortex, across 10 coronal levels (rostral to caudal), with CBF that is severely (0%--43%), moderately (43%--75%) and mildly (75%--100%) reduced relative to the contralateral cortex (b). Data are presented as mean ± standard deviation. Differences between groups are not statistically significant: two-way ANOVA.](10.1177_2398212818794820-fig2){#fig2-2398212818794820}

###### 

Normalised ^99m^Tc-HMPAO concentrations in 22 distinct brain regions following occlusion of the middle cerebral artery for 1 h.

![](10.1177_2398212818794820-table3)

  Normalised ^99m^Tc-HMPAO concentration (% of contralateral region)                         
  -------------------------------------------------------------------- ---------- ---------- ------
  Motor cortex                                                         57 ± 18    60 ± 26    0.81
  Auditory cortex                                                      54 ± 28    53 ± 28    0.89
  Visual cortex                                                        50 ± 15    63 ± 23    0.43
  Primary somatosensory cortex                                         18 ± 15    12 ± 5     0.22
  Secondary somatosensory cortex                                       35 ± 19    25 ± 18    0.42
  Anterior cingulate cortex                                            77 ± 16    81 ± 18    0.53
  Medial cingulate cortex                                              96 ± 15    87 ± 21    0.29
  Lateral orbital cortex                                               60 ± 28    62 ± 22    0.88
  Insular cortex                                                       68 ± 28    55 ± 19    0.21
  Prelimbic cortex                                                     78 ± 21    80 ± 18    0.80
  Piriform cortex                                                      89 ± 21    94 ± 19    0.56
  Caudate putamen medial                                               95 ± 17    95 ± 9     0.87
  Caudate putamen lateral                                              103 ± 20   98 ± 26    0.60
  Hippocampus                                                          106 ± 14   102 ± 5    0.31
  Globus pallidus                                                      112 ± 13   111 ± 11   0.85
  Nucleus accumbens                                                    99 ± 12    99 ± 10    0.92
  Amygdala                                                             105 ± 15   105 ± 12   0.95
  Hypothalamus                                                         99 ± 10    98 ± 5     0.88
  Thalamus                                                             103 ± 5    101 ± 7    0.40
  Substantia nigra                                                     105 ± 8    110 ± 11   0.20
  Septum                                                               98 ± 7     99 ± 6     0.56
  Corpus callosum                                                      100 ± 8    89 ± 10    0.40

Data are presented as means ± standard deviations (vehicle n=10; glucose n=11). Differences between groups are not statistically significant: Student's unpaired t-test.

MRI perfusion imaging {#section23-2398212818794820}
---------------------

The results from the MRI perfusion experiments are presented in [Figure 3](#fig3-2398212818794820){ref-type="fig"}. Quantitative pCASL CBF maps acquired at 1 and 4 h post-MCAO from the median animal of each group are presented in [Figure 3(a)](#fig3-2398212818794820){ref-type="fig"}. Darker regions on the CBF maps represent regions of reduced CBF and the region of reduced blood flow induced by MCAO was detected in the ipsilateral cortex of all six coronal slices in both groups, at both time points. At each time point after MCAO, the mean volume of the perfusion deficit tended to be larger in the glucose group compared to the vehicle group ([Figure 3(b)](#fig3-2398212818794820){ref-type="fig"}), but the difference between groups was not statistically significant. The volume of the perfusion deficit tended to increase over time in both groups. In the vehicle group, the mean perfusion deficit volume increased from 140 ± 37 mm^3^ at 1 h post-MCAO to 151 ± 42 mm^3^ at 4 h but the difference was not statistically significant. Similarly, in the glucose group, the mean perfusion deficit volume increased from 164 ± 40 to 192 ± 54 mm^3^ between 1 and 4 h post-MCAO, respectively.

![Quantitative CBF maps displaying hypoperfused tissue at 1 and 4 h post-MCAO over six coronal slices (a). The darker regions represent areas with reduced blood flow and these were predominantly in the ipsilateral cortex, as a result of distal MCAO. Temporal evolution of the perfusion deficit 1--4 h after MCAO (b). The perfusion deficit volume was calculated by applying an abnormal perfusion threshold of 30 mL/100 g/min to CBF maps. Data are presented as mean ± standard deviation. Differences between groups are not statistically significant: repeated measures two-way ANOVA with Bonferroni's post-test.](10.1177_2398212818794820-fig3){#fig3-2398212818794820}

ADC lesion volume and T~2~-derived infarct volume {#section24-2398212818794820}
-------------------------------------------------

The spatial profiles of the ADC lesions at 1 and 4 h post-MCAO from the median animal of each group are presented in [Figure 4(a)](#fig4-2398212818794820){ref-type="fig"}. In the glucose animal, the ADC lesion is anatomically more widespread than in the vehicle animal. At 1 h after MCAO, there was no significant difference in the mean ADC-defined lesion volume between the vehicle and glucose groups ([Figure 4(b)](#fig4-2398212818794820){ref-type="fig"}). However, ADC lesion volumes measured at 2, 3 and 4 h after MCAO were significantly greater in the glucose group compared to the vehicle. T~2~-derived infarct volume measured 24 h after MCAO was significantly greater in glucose compared to vehicle-treated rats ([Figure 5(a)](#fig5-2398212818794820){ref-type="fig"}. The mean T~2~-derived infarct volume was 57 ± 22 and 90 ± 19 mm^3^ in vehicle- and glucose-treated rats, respectively. There was a significant, positive linear correlation between T~2~-derived infarct volume at 24 h and blood glucose levels 4 h after MCAO in rats that received glucose (R^2^ = 0.43) but not vehicle (R^2^ = 0.15) ([Figure 5(b)](#fig5-2398212818794820){ref-type="fig"}). Thus, hyperglycaemia increased acute ADC lesion volume and infarct volume 24 h after MCAO.

![Apparent diffusion coefficient (ADC) lesions at 1 h (white areas) and 4 h (red areas) post-MCAO across the equivalent six coronal slices (a). The images are from the median animal of the vehicle and glucose treatment groups. ADC-derived lesion volume measured 1--4 h after MCAO (b). ADC lesion volume was calculated by applying an abnormal diffusion threshold of 0.53 × 10^−3^ mm^2^/s. Data are presented as mean ± standard deviation. \*P \< 0.05 compared with vehicle rats using a repeated measures two-way ANOVA with Bonferroni's post-test.](10.1177_2398212818794820-fig4){#fig4-2398212818794820}

![Scatter plot showing the T~2~-derived infarct volumes measured 24 h after MCAO in each rat (a). The horizontal line on the scatter plot represents the mean. \*P \< 0.05 compared with vehicle group using a Student's unpaired t-test. A Pearson's correlation was performed between the T~2~-derived infarct volume and blood glucose levels measured at 4 h post-MCAO in the vehicle and glucose groups (b). There was a significant, positive correlation between T~2~-derived infarct volume and blood glucose levels in rats that received glucose (R^2^ = 0.43, P = 0.04) but not vehicle (R^2^ = 0.15, P = 0.3).](10.1177_2398212818794820-fig5){#fig5-2398212818794820}

Perfusion--diffusion mismatch and ADC-derived penumbra {#section25-2398212818794820}
------------------------------------------------------

The volume of tissue with perfusion--diffusion mismatch ([Figure 6(a)](#fig6-2398212818794820){ref-type="fig"}), an estimate of the volume of the ischaemic penumbra, was comparable between groups at each time point post-MCAO ([Figure 6(b)](#fig6-2398212818794820){ref-type="fig"}). The mean perfusion--diffusion mismatch volumes at 1 h post-MCAO were 103 ± 31 and 117 ± 36 mm^3^ in vehicle- and glucose-treated rats, respectively. The volume of perfusion--diffusion mismatch tissue did not change significantly over time in either group as the mismatch volume at 4 h post-MCAO was 108 and 130 mm^3^ in vehicle- and glucose-treated rats, respectively. It is important to mention here that although the volume of mismatch tissue measured at each hour after the onset of MCAO does not significantly change between 1 and 4 h in each group, the tissue within the penumbra will inevitably change over time. Some of the tissue with perfusion--diffusion mismatch will become incorporated into the infarct and this is supported by the fact that the ADC lesion increased over time in both vehicle and glucose treatment groups. Also, as collateral blood supply decreases over time (supported by the decrease in CBF observed in the contralateral hemisphere ([Figure 3(a)](#fig3-2398212818794820){ref-type="fig"}), some of the benign oligaemic tissue will become incorporated into the ischaemic penumbra. Therefore, while the volume of presumed penumbra does not change over time, the tissue compartment defined by the perfusion-diffusion mismatch will have.

![Spatial distributions of perfusion--diffusion mismatch tissue across six coronal slices (caudal to rostral) at 1 and 4 h after MCAO (a). The images displayed are from the median animal of each group. The red region depicts the perfusion deficit defined by applying an absolute threshold of 30 mL/100 g/min. The white region depicts the ADC lesion defined by applying an ADC threshold of 0.53 × 10^−3^ mm^2^/s. On slices where there was a perfusion deficit but no ADC lesion the perfusion deficit area was considered as mismatch tissue. Perfusion--diffusion mismatch volumes 1--4 h post-MCAO (b). There was no statistical difference between vehicle- and glucose-treated groups by repeated measures two-way ANOVA.](10.1177_2398212818794820-fig6){#fig6-2398212818794820}

Degradation of MAP2 and spectrin levels in ischaemic cortex {#section26-2398212818794820}
-----------------------------------------------------------

The degradation of microtubule-associated protein 2 (MAP2) and spectrin by the calcium-dependent cysteine protease calpain was assessed as a marker of ischaemic brain damage. Calpain cleaves αII-spectrin (280 kDa) producing two spectrin breakdown products (SBDPs) at approximately 150 and 145 kDa. In the Western Blot for αII-spectrin, a doublet band representing intact spectrin was observed at 280 kDa in all samples from the vehicle treatment group but was not observed in two rats from the glucose treatment group (G1 and G4) ([supplementary Figure 1S](http://journals.sagepub.com/doi/suppl/10.1177/1129729818783965)). A doublet band representing calpain-mediated SBDPs was observed at 150--155 kDa in all rats. In the two glucose-treated rats, in which a band at 280 kDa was not observed (G1 and G4), an intense band at 150 kDa was observed suggesting a greater extent of calpain-mediated spectrin breakdown in these samples. When the values of the SBDP bands were expressed as a ratio of the β-actin bands, to account for sample loading differences, the relative protein levels of SBDPs were significantly greater in glucose compared to vehicle-treated rats ([Figure 1S](http://journals.sagepub.com/doi/suppl/10.1177/1129729818783965)), suggesting that glucose treatment increased calpain-mediated αII-spectrin breakdown. In the Western blot for MAP2, a band representing MAP2 (high molecular weight isoforms) was observed at approximately 270--280 kDa in most samples ([supplementary Figure 2S](http://journals.sagepub.com/doi/suppl/10.1177/1129729818783965)). The intensity of this MAP2 band varied among samples indicating differing amounts of MAP2 degradation. The intensity was greatest in the control sample (C) where MAP2 proteolysis was expected to be minimal. There was no significant difference in relative MAP2 protein levels ([Figure 2S](http://journals.sagepub.com/doi/suppl/10.1177/1129729818783965)) between glucose and vehicle treatment groups, although relative MAP2 protein levels in glucose-treated rats tended to be lower than vehicle-treated rats.

Discussion {#section27-2398212818794820}
==========

In a model of focal cerebral ischaemia, clinically relevant levels of hyperglycaemia exacerbated the very early evolution of ischaemic brain damage, despite a lack of effect on the volume of perfusion deficit or ischaemia severity, as determined by different methods of CBF measurement. Hyperglycaemia is consistently associated with worse outcomes in both clinical and animal stroke studies. The results reported here support these findings, demonstrating that hyperglycaemia, at levels typically observed in stroke patients, increases acute ischaemic damage and infarct volume in a normotensive rat strain. The rationale for choosing a normotensive rat strain was based on evidence from clinical and preclinical studies demonstrating that hyperglycaemic patients or animals without co-morbidities (diabetes, metabolic syndrome) had worse outcomes from stroke in comparison to those with additional co-morbidities ([@bibr6-2398212818794820]; [@bibr38-2398212818794820]; [@bibr43-2398212818794820]). The pathophysiological mechanisms underlying the association between hyperglycaemia and poor outcomes from acute ischaemic stroke are unclear. The data from our present study and from previous studies ([@bibr18-2398212818794820]; [@bibr43-2398212818794820]) show that the detrimental effects of hyperglycaemia occur early, within the first 1--2 h after permanent MCAO leading to significantly larger infarcts. Given this early time-window, and because acute hyperglycaemia has been shown to affect CBF ([@bibr10-2398212818794820]; [@bibr11-2398212818794820]), we sought to determine whether hyperglycaemia increases ischaemic damage by increasing the volume or severity of the perfusion deficit induced following permanent occlusion of the MCA. We measured cerebral perfusion using two different methods and the results from each demonstrate that hyperglycaemia, at clinically relevant levels, does not induce a significant increase in the severity of hypoperfusion during the first 4 h following MCAO. Previous studies of hyperglycaemia in animal models of stroke have reported similar findings ([@bibr8-2398212818794820]; [@bibr14-2398212818794820]; [@bibr25-2398212818794820]; [@bibr32-2398212818794820]; [@bibr44-2398212818794820]). For example, Gisselsson and colleagues investigated the influence of hyperglycaemia (20 mmol/L) on tissue damage and CBF in rats during and after transient MCAO. In hyperglycaemic rats, tissue damage after 30 min MCAO was significantly greater compared to normoglycaemic rats but there was no difference in CBF ([@bibr14-2398212818794820]). In contrast to previous studies, we examined the effects of hyperglycaemia at levels typically observed in patients. In the majority of previous studies, hyperglycaemic animals had blood glucose levels \>20 mmol/L, with values exceeding 40 mmol/L in some cases ([@bibr25-2398212818794820]). These values far exceed the blood glucose levels classified as hyperglycaemic in patients. For example, in clinical trials investigating insulin treatment for PSH, blood glucose levels in hyperglycaemic patients ranged from \~7 to 10 mmol/L ([@bibr15-2398212818794820]; [@bibr19-2398212818794820]). Physiological blood glucose concentrations are closely regulated and ranged from 4 to 6 mmol/L. Therefore, clinically, only minor increments in blood glucose levels (\~1--6 mmol/L) are defined as PSH and have been associated with poorer clinical outcomes. In our animal model, the blood glucose difference between vehicle and glucose-treated rats was \~6 mmol/L, with mean blood glucose values in hyperglycaemic animals (\~12 mmol/L) closer to those seen in stroke patients. In one of the few clinical studies to examine perfusion deficits in stroke patients with PSH, mean blood glucose levels in normoglycaemic and hyperglycaemia patients were 5.9 and 9.5 mmol/L, respectively, on admission ([@bibr22-2398212818794820]). In the aforementioned study, Luitse and colleagues reported that patients with admission hyperglycaemia did not have larger volumes of hypoperfusion compared to normoglycaemic patients during the acute stage (\<24 h) of ischaemic stroke ([@bibr22-2398212818794820]). Thus, our results are in agreement with these clinical findings and support the supposition that the detrimental effects of hyperglycaemia in ischaemic stroke are not associated with larger volumes of hypoperfusion.

Although we did not find an effect of hyperglycaemia on cerebral perfusion in our study, hyperglycaemia exacerbated the evolution of ischaemic brain damage, as reflected by larger ADC lesions as early as 2 h after MCAO. This agrees with our previous findings in the Wistar-Kyoto (WKY) and spontaneously hypertensive stroke-prone rat strains where the effects of hyperglycaemia on ADC lesion volume growth were evident as early as 1 h after MCAO ([@bibr43-2398212818794820]). One limitation of both studies is that we did not include an isotonic control for glucose-treated group. However, the weight of evidence from clinical studies of stroke patients indicates that naturally occurring hyperglycaemia is associated with poorer outcome than euglycaemia (see above). The pathophysiological mechanisms by which hyperglycaemia increases early ischaemic damage have not been fully elucidated. Possible mechanistic explanations include impaired recanalisation and increased reperfusion injury, increased lactic acidosis, enhancing excitotoxicity and increased oxidative stress and inflammation. Of these many mechanisms, the anaerobic metabolism of glucose through the lactic acid cycle was the first and is the most persistent hypothesis used to explain the relationship between hyperglycaemia and poor outcomes from ischaemic stroke. In the absence of oxygen, glucose is metabolised anaerobically producing lactate as a by-product. Elevated lactate levels can acidify cells and the surrounding environment leading to tissue acidosis. This is potentially damaging and can lead to the production of free radicals and mitochondrial dysfunction ([@bibr1-2398212818794820]; [@bibr33-2398212818794820]), both of which would be detrimental during ischaemia. Both clinical and experimental studies have revealed an association between hyperglycaemia and increased brain lactate levels. Furthermore, elevated lactic acid concentrations have been shown to correlate with worse outcomes ([@bibr1-2398212818794820]; [@bibr21-2398212818794820]). Although there appears to be strong evidence indicating increased lactate as an important mediator of hyperglycaemia-induced brain damage, the fact that lactate metabolism is important for ATP production during ischaemia ([@bibr31-2398212818794820]), and that inhibiting lactate production during ischaemia exacerbates, rather than reduces, ischaemic damage ([@bibr7-2398212818794820]), suggests that it is not the only contributor.

During the acute 1--2 h following MCAO, when hyperglycaemia had the biggest impact on lesion size, we wanted to determine whether hyperglycaemia had any influence on the volume of penumbra tissue as results from a clinical study demonstrated that larger infarcts in patients with PSH were associated with reduced salvage of penumbra tissue ([@bibr29-2398212818794820]). The MRI data produced in our study allowed us to investigate the ischaemic penumbra by measuring the volume of perfusion--diffusion mismatch tissue. We found that hyperglycaemia did not significantly alter the volume of perfusion--diffusion mismatch tissue over the first 4 h after MCAO compared to control. We used a threshold of 30 mL/100 g/min to establish the volume of tissue with a perfusion deficit in our pCASL CBF maps. This may have resulted in an overestimation of the perfusion deficit, as the tissue with a perfusion deficit was not all incorporated into the infarct measured at 24 h. For example, in the group that received glucose, the perfusion deficit at 4 h was 192 mm^3^ whereas the ADC lesion volume and T~2~-derived infarct volumes were 81 and 90 mm^3^, respectively. A potential explanation why most of the perfusion deficit was not incorporated into the final infarct could be the increase in blood pressure that occurs on withdrawal of anaesthesia. Withdrawal of isoflurane, which is known to have a cardio-depressant effect ([@bibr36-2398212818794820]), will inevitably lead to a rise in blood pressure as animals regain consciousness. This increase in blood pressure may cause an increase in CBF within the ischaemic hemisphere, reducing the volume of the perfusion deficit and preventing the progression of the hypoperfused at-risk tissue to infarction.

If the adverse effects of hyperglycaemia after stroke are not predominantly mediated at the level of the cerebrovasculature through increased severity of hypoperfusion, the alternative is that the effects take place mainly within brain tissue. In our previous study of hyperglycaemia and MCAO, we reported a small increase in the levels of 4-hydroxynonenal, a marker of oxidative stress, within the infarcts of hyperglycaemic compared to normoglycaemic rats. But this was only detected in normotensive WKY rats, not in fructose-fed, spontaneously hypertensive stroke-prone rats, a model of metabolic syndrome ([@bibr43-2398212818794820]). In the current study, infarcted tissue was examined by Western blotting for markers of calcium-dependent calpain activity, breakdown of MAP2 and spectrin ([@bibr2-2398212818794820]; [@bibr9-2398212818794820]; [@bibr48-2398212818794820]), as a means of indirectly assessing excitotoxic mechanisms which are known to be involved in ischaemic damage to neurons. There was a modest increase in spectrin breakdown in glucose -- compared to vehicle-treated animals, but no difference between groups in the levels of MAP2 in the infarcted tissue ([supplementary Figures 1S](http://journals.sagepub.com/doi/suppl/10.1177/1129729818783965) and [2S](http://journals.sagepub.com/doi/suppl/10.1177/1129729818783965)). Although not definitive, these observations are consistent with the conclusion that a single predominant mechanism leading to hyperglycaemia-induced exacerbation of neuronal damage is unlikely. However, we only examined tissue that was already infarcted as it was available at the end of the MRI study. Therefore, it would be interesting to examine brain tissue at earlier time points when the damage is evolving and given the complexity of the ischaemic cascade, it may be fruitful to use preparations such as acute in vitro slice preparations for future mechanistic studies.

In conclusion, this study demonstrates the lack of a profound effect of hyperglycaemia on the severity and extent of ischaemia after MCAO in the rat. However, the data reinforce the view that the detrimental effects of hyperglycaemia on brain tissue occur rapidly in the ischaemic brain. A plausible hypothesis may therefore be that hyperglycaemia influences multiple pathophysiological mechanisms simultaneously that combine to exacerbate injury. This could include influences on cerebrovascular function that are too subtle to be detected by the methods we employed to measure CBF. Future clinical trials of glucose lowering therapies are only likely to show benefit if they are initiated early after stroke onset.
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